Clinical trials in JON-HBP

1/11/2024 updated

JON2101-H Randomized phase III trial of Lenvatinib versus Ramucirumab as a second-line treatment after immune check-point inhibitor for advanced hepatocellular carcinoma with alfa-fetoprotein >400 ng/mL (SELECT-400)
JON2102-H Randomized phase III trial of Sorafenib versus Lenvatinib as a second-line treatment after immune check point inhibitor for advanced hepatocellular carcinoma (JON2102-H (SUCCEED)
JON2104-B Analysis of a multicenter, prospective non-interventional study of chemotherapy in elderly patients with biliary tract cancer (JON2104-B)
JON2103-H Phase II study of atezolizumab plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma and Child-Pugh B (CHALLENGE trial)
JON2106-P A multicenter retrospective observational study for pulmonary resection in pulmonary origometastasis after pancreatectomy
JON2108-O Master protocol trial for rare fractions of hepato-pancreato-biliary cancer and neuroendocrine tumor.
JON2109-P Comparison between nanoliposomal irinotecan plus 5-FU/ folinic acid and S-1 monotherapy in metastatic pancreatic cancer: A propensity score-matched retrospective cohort study
JON2107-B Efficacy and safety of FOLFOX for patients with unresectable or recurrent biliary tract cancer as second or later line treatment
JON2201-P The effect of adjuvant chemotherapy on the prognosis in the patients with familial pancreatic cancer
JON2301-H Lenvatinib plus cisplatin hepatic arterial infusion chemotherapy for borderline resectable hepatocellular carcinoma: A Multicenter Phase II Study(LEOPARD-Neo)
JON2105-P Phase II study of FOLFOX for unresectable pancreatic cancer patients with germline BRCA pathogenic variant
JON2202-B A multicenter single arm phase I study of concurrent radiation and gemcitabine plus cisplatin with durvalumab (MEDI4736) for advanced biliary tract cancer (MARVEL trial)
JON2302-P A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy